|
Clinical Trials at Tulane University Cancer Center A list of clinical trials organized by disease site is provided by Tulane University Cancer Center to help patients and physicians identify clinical trials in which they may have been participating prior to Hurricane Katrina. Links to NCI's PDQ® Clinical Trial Registry trial descriptions are included and can be used to identify alternate trial sites.
AIDS-Related Cancers
Brain
Breast
Gastro-intestinal
Genito-urinary
Gynecologic
Head and Neck
Leukemia
Liver
Lung
Lymphoma
Melanoma
Multiple Myeloma
Neuroblastoma
Soft Tissues Sarcoma
Hematopoietic Failure and Genetic Disease Transplant Studies
General protocols
AIDS-Associated Malignancies Clinical Trials Consortium (AMC)
| AMC 036 1 |
A Phase II Trial of Topical Halofuginone in Patients with HIV Related Kaposi's Sarcoma. |
| Tulane # LN01.1
IRB 10/11/01 |
BRAIN (Metastases): Local therapy for limited metastatic disease to the brain: A Phase II study of surgery, SRS, and SRT in favorable patients.
* Tulane investigator-initiated study |
COG # A9952 2
Closed |
Chemotherapy for progressive low-grade astrocytoma in children younger than ten years old. |
| COG # P9934 3 |
Systemic chemotherapy, second look surgery, and involved field radiation for children >= 8 months and <= 36 months with non-metastatic medulloblastoma. |
RTOG # 04-20 4
IRB 03/15/2005 |
A Phase II study of radiation therapy plus low-dose Temozolomide followed by Temozolomide plus Irinotecan for glioblastoma multiforme. |
NSABP # B-35 5
IRB 04/04/03 |
BREAST: A clinical trial comparing Anastrozole with Tamoxifen in post-menopausal patients with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy. |
NSABP # B-36 6
IRB 07/28/2004 |
BREAST: A clinical trial of adjuvant therapy comparing six cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC), with or without Celecoxib, in patients with node-negative breast cancer.
|
NSABP # B-38 7
IRB 11/11/2004 |
BREAST: A Phase III adjuvant trial comparing three chemotherapy regimens in women with node-positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC-->P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC-->PG).
|
NSABP # P-2 8
(STaR) 9
IRB 5/10/99
Closed to accrual 09/2004 |
Study of Tamoxifen and Raloxifene (STaR) for the prevention of breast cancer.
See further
information on STaR trial 10. |
NSABP # N01-AG-1-2106
(co-STAR)
IRB 12/20/01 |
Study of Tamoxifen and Raloxifene (STaR) for the prevention of breast cancer.
See further
information on STaR trial 10. |
SWOG # S0221 11
IRB 02/29/2004 |
BREAST: Phase III trial of continuous schedule AC+G vs. Z 2-week schedule AC, followed by Paclitaxel given either every 2 weeks or weekly for 12 weeks as post-operative adjuvant therapy in node-positive or high-risk node negative breast cancer.
|
SWOG # S0338 12
IRB 01/13/2005
Temp. closure
04/15/2005 |
BREAST: A Phase II trial of Imatinib Mesylate (Gleevec) in combination with Capecitabine (Xeloda) in metastatic breast cancer.
|
Anal
RTOG # 03-15 13
IRB 07/20/2004 |
ANAL: A randomized, double-blind, placebo-controlled Phase III study to determine the efficacy of Sandostatin LAR (Ochtreotide Acetate) in preventing or reducing the Severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer.
Details 14
on RTOG website in PDF format.
|
Colorectal
NSABP # C-08 15
IRB 10/04/2004 |
A Phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX6) every two weeks with Bevacizumab to the same regimen without Bevacizumab for the treatment of patients with resected Stages II and III carcinoma of the colon.
|
NSABP # R-04 16
IRB 10/12/2004 |
A clinical trial comparing pre-operative radiation therapy and Capecitabine with pre-operative radiation therapy and continuous intravenous infusion (CVI) of 5-Fluorouracil (5-FU) in the treatment of patients with operable carcinoma of the rectum.
|
Esophageal Gall bladder
SWOG # S0202
Closed
|
A Phase II trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in patients with unresectable or metastatic gall bladder or cholangiocarcinoma. |
SWOG # S0415 17
transplant
IRB 01/07/2005 |
Cetuximab As Second Line Therapy In Patients With Metastatic Esophageal Cancer - Phase II |
Pancreas
TBC-PAN-003 18
IRB 08/16/2004 |
A Phase III randomized, controlled study to evaluate the safety and efficacy of PANVAC in combination with GM-CSF vs. best supportive care of palliative chemotherapy in patients with metastatic (Stage IV) adenocarcinoma of the pancreas who have failed a Gemcitabine-containing chemotherapy regimen.
|
Bladder
SWOG # 4B951 19
IRB 03/12/03 |
MVAC in organ-confined bladder cancer based on p53 status. |
Prostate
SWOG 20 # 9205 21
IRB 8/26/93 |
Companion to any SWOG PROSTATE CANCER study: Central Prostate Cancer Serum Repository |
SWOG # S0000 22
IRB 8/9/01
Closed
June 2004 |
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer, Phase III.
|
SWOG 20 # S0000A 23
IRB 01/02/03 |
Prevention of Alzheimer's Disease with Vitamin E and Selenium (PREADVISE): Phase III ancillary to
S0000-SELECT 22
|
SWOG # P9346 24
IRB 10/26/95 |
PROSTATE: (Stage IV) Induction: Flutamide + luprondepotor) zoladex). Consolidation: continuous androgen deprivation vsl. intermittent androgen deprivation.
|
SWOG # S9917 25
IRB 7/12/01 |
PROSTATE: (Prevention): "L-Selenium-based chemoprevention of prostate cancer among men with high-grade prostatic intraepithelial neoplasis"
|
SWOG # S9921 26
IRB 1/10/00 |
PROSTATE: Adjuvant androgen deprivation versus Mitoxantrone plus Prednisone plus androgen deprivation in selected high risk prostate cancer patients following radical prostatectomy, phase III
|
SWOG # JPR.3 27
IRB 12/12/96 |
PROSTATE: (T3-4, N0, M0) Phase III comparing total androgen blockade vs. total androgen blockade + pelvic irradiation.
|
SWOG # JPR.7 28
IRB 12/28/99 |
PROSTATE: Intergroup phase III randomized trial comparing intermittent vs. continuous androgen suppression for patients with prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer
|
Kidney (Renal)
COG
# NWTSG 4941 29
Closed |
WILMS' TUMOR: National Wilms' Tumor study V. Therapeutic trial and biology study |
COG
# NWTSG 4942 30
Closed |
WILMS' TUMOR: Treatment of relapsed patients. A national Wilms Tumor study group Phase III study. |
Cervical
GOG
# 179 31
Closed
IRB ok 11/6/00 |
CERVICAL: (Stage IVB) A randomized Phase III study of Cisplatin vs. Cisplatin plus Topotecan vs. MVAC in Stage IVB, recurrent or persistent carcinoma of the cervix.
|
GOG # 191 32
Closed |
CERVICAL: (Stage IIB, IIIB, IVA) A Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 120 G/L with erithropoietin vs. above 100 G/L without erithropoietin in anemic patients receiving concurrent radiation and cisplatin and cervical cancer.
|
Endometrial
GOG # 137 33
Closed |
ENDOMETRIAL: (Stage I, II) A randomized double-blinded trial of estrogen replacement therapy vs. placebo in women with Stage I or II endometrial adenocarcinoma.
|
GOG # 184 34
Closed |
ENDOMETRIAL: A randomized Phase III study of tumor volume-directed pelvic +/- para-aortic irradiation followed by Cisplatin and Doxorubicin or Cisplatin, Doxirubicin and Paclitaxel for advanced endometrial carcinoma.
|
Ovarian
| # C0307 35 |
OVARIAN: A Phase I/II trial of intravenous Ontak to treat epithelial ovarian cancer FIGO Stage III or Stage IV, or extraovarian peritoneal carcinoma, failing or ineligible for first-line therapy.
A Tulane-initiated study. |
| GOG # 136 |
OVARIAN: (All stages): Acquisition of human gynecological specimens and serum to be used in studying the causes, diagnosis, prevention and treatment of cancer.
|
| GOG # 175 36 |
OVARIAN: (Early stage): 175mg/m2 q 21 days x 3 courses plus low dose Paclitaxel 40 mg/m3/wk vs. IV Carboplatin (AUC6) and Paclitaxel 174mg/m2 q 21 days x 3 courses plus observation in patient with early stage ovarian carcinoma.
|
| GOG
# 182 37
|
OVARIAN: (Stage III, IV): A Phase III randomized trial of Paclitaxel and Carboplatin vs. triplet or sequential doublet combinations in patients with epithelial ovarian carcinoma or primary peritoneal carcinoma.
|
| GOG # 199 38 |
OVARIAN: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer.
|
Sarcoma
| GOG # 161 39 |
SARCOMA: A phase III trial of Ifosfamide (NSC#109724) versus Ifosfamide plus Paclitaxel (NSC#125973) in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal tumors) of the uterus).
|
Trophoblastic Neoplasia
GOG # 174 40
IRB 6/14/99 |
LOW-RISK: A randomized Phase III trial of weekly parenteral methotrexate vs. 'pulsed' dactinomycin as primary management for low-risk gestational trophoblastic neoplasia.
|
GOG # 176 41
Closed
IRB 10/18/99
|
FAILED LOW-RISK: A Phase II trial of pulse Acgtinomycin-D as salvage therapy for failed low-risk gestational trophoblastic neoplasia
|
RTOG # 0225 42
IRB 05/28/2003 |
A Phase II study of intensity-modulated radiation therapy (IMRT) +/- chemotherapy for nasopharyngeal cancer.
|
| RTOG # 0234 43 |
A Phase II randomized trial of surgery followed by chemoradiotherapy plus c225 (Cetuximab) for advanced squamous cell carcinoma of the head and neck.
Details 44 on RTOG website in PDF format.
|
General
SWOG 20 # 9007 45
IRB 9/12/91 |
Companion to any SWOG LEUKEMIA study: Cytogenetics (marrow) |
Acute Leukemia
SWOG 20 # 9910 46
IRB 2/17/00 |
ANCILLARY: Leukemia centralized reference laboratories and tissue repositories |
SWOG # S0301 47
IRB 03/11/2004 |
A Phase II study of induction with Daunorubicin, Cytarabine, and Cyclosporine all by continuous IV infusion for previously untreated non-M3 acute myeloid leuemia (AML) in patients age 56 or older.
Temporary closure as of March 2004. |
SWOG # S0432 48
IRB 01/07/2005 |
A Phase II study of two different schedules and two different doses of the farnesyl transferase inhibitor R115777 (Tipifarnib, Zarnestra, NSC-702818) for previously untreated acute myeloid leukemia (AML) in patients age 70 or older.
|
| Tulane BMT # 98-1
IRB 11/10/98 |
TRANSPLANT: Bone marrow transplant for high-risk LEUKEMIAS with busulfan, CTX, and Etoposide
* Tulane investigator-initiated study |
Chronic Leukemia
| BMT # 2000-01
IRB 1/25/00 |
CML in the first chronic phase. Allogeneic BMT for chronic myelogenous leukemia using primed bone marrow stem cells.
*Tulane investigator-initiated study. |
COG 49 Leukemia studies
| COG # P9407 50 |
Induction intensification and allogeneic bone marrow transplant in infant ALL: A COG pilot study. |
| COG #
P9900 49
|
ALinC17: Leukemia cell classification protocol |
| COG # P9904 51 |
ALinC17: Treatment for patients with low-risk acute lymphoblastic leukemia
Temporary closure
|
COG
# P9905 52
Closed |
ALinC17: Protocol for patients with newly-diagnosed standard-risk acute lymphoblastic leukemia (ALL).
|
| COG # P9907 |
ALinC17: Cytogenetics protocol |
| COG # AALL0031 53 |
Pilot study for the treatment of very-high-risk acute lymphoblastic leukemia (ALL) in children and adolescents (ST1571 NSC#716051/IND#61135). Phase III group-wide pilot study.
|
| COG # ADVL0022 54 |
Phase II study of Gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (AML)
|
| COG # ADVL0023 55 |
Phase II study of Docetaxel (Taxotere) (NSC#628503) in children with refractory leukemias
|
COG
# ADVL0122 56
Closed
|
Phase II trial of Gleevec (Imatinib Mesylate, formerly ST1571) in children with refractory or relapsed solid tumors.
|
| COG
# AS9801 49 |
ANCILLARY: Second malignant neoplasms following childhood cancer.
|
| COG # DFCI ALL 2000-01 |
Dana Farber Cancer Institute (DFCI) ALL Consortium Protocol 2000-01: Treatment of acute lymphoblastic leukemia (ALL) in children, both high-risk and standard-risk.
Submitted to IRB.
|
# COM 02-721
IRB 11/17/2003 |
Multi-institution Phase I/II dose escalation study of body stereotactic hypofractionated radiation therapy for liver metastases.
|
# MB 04-01
IRB 11/12/2004 |
Phase II study of arsenic trioxide in combination with ascorbic acid in hepatocellular carcinoma.
|
NSABP
# CI-66 57
Closed
IRB 01/15/2004 |
A Phase II trial evaluating multiple metastatectomy combined with hepatic artery infusion of Floxuridine (FUDR) and Dexamethasone (DXM), alternating with systemic Oxaliplatin (OXAL) and Capecitabine (CAPCIT) for colorectal carcinoma metastatic to the liver.
Closed to accrual. |
| COG # P9346 |
Hepatoblastoma biology study and tissue bank |
| COG # P9645 58 |
Phase III intergroup protocol for the treatment of children with hepatoblastoma. |
SWOG 20 # S9925 59
IRB 03/14/02 |
Lung cancer specimen repository protocol. |
SWOG # S0310 60
IRB 06/09/2004
Closed |
Phase II trial of CG8123, an autologous cancer vaccine (GVAX) in patients with Stage IIIB and IV bronchiloaveolar carcinoma (BAC)
|
SWOG # S0124 61
IRB 05/16/2003 |
Randomized Phase III trial of Cisplatin and Irinotecan (NSC-616348) vs. Cisplatin and Etoposide in patients with extensive stage small-cell lung cancer (E-SCLC)
|
Non-small-cell Lung
SWOG # E5597 62
IRB 6/14/01 |
(Post-op, Stage IA, pT1N0 or Stage IB, pT1N0) "Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small-Cell Lung Cancer"
|
SWOG # S0342 63
IRB 01/07/2005
Closed |
Phase II selection design trial of concurrent chemotherapy + Cetuximab vs. chemotherapy followed by Cetuximab in advanced non-small cell lung cancer (NSCLC)
|
| RTOG # 0236 64 |
A Phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable Stage I/II non-small cell lung cancer.
Details 65 on RTOG website in PDF format.
|
Small-cell Lung: None currently open
Hodgkin's Lymphoma
SWOG # E2496 66
IRB 12/31/99 |
Randomized phase III trial of ABVD versus Stanford v +/- radiation therapy in locally extensive and advanced stage Hodgkin's disease with 0-2 risk factors.
|
| COG # AHOD0031 67 |
Phase III group-wide study of dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly-diagnosed intermediate-risk Hodgkin's disease.
|
| COG # AHOD00P1 68 |
A pilot study of re-induction chemotherapy with Ifosfamide and Vinorelbine (IV) in children with refractory/relapsed Hodgkin's Disease
|
Non-Hodgkin's Lymphoma
SWOG # 8819
transplant
IRB 10/11/90 |
Companion to 9320, 9703, 9704,
9800 (Non-Hodgkin's Lymphoma): Central lymphoma repository tissue procurement. |
SWOG # S9704 69
IRB 12/29/97 |
Non-Hodgkin's Lymphoma (diffuse, aggressive, intermediate & high risk): Phase III trial comparing early high dose chemoradiotherapy (4 cycles CHOP) + autologous stem cell transplant to 8 cycles CHOP. (Temporary Closure 5/15/99)
|
Tulane BMT #
99-2
IRB 2/24/00 |
Autologous transplantation for non-Hodgkin's lymphoma. The role of in vivo purging with monoclonal antibody. |
| COG # A5971 70 |
A randomized Phase III study for the treatment of newly-diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic lymphoma.
|
AIDS-related Non-Hodgkin's Lymphoma
SWOG # 8947
IRB 5/10/90 |
Companion to SWOG S9704 69: Central serum repository (mandatory)
|
| SWOG # 9245
IRB 05/13/93 |
Companion to SWOG S9704 69: Central lymphoma repository tissue procurement protocol for relapsed or recurrent disease (optional)
|
T-cell Lymphoma
| |
Phase II Study- Arsenic Trioxide in Patients with Cutaneous T-Cell Lymphoma (CTI) |
None currently open.
Tulane BMT # 99-1
IRB 08/02/99 |
MULTIPLE MYELOMA: Immuno-transplantation for lymphoid malignancy using allogeneic blood stem cells. |
Tulane # HSO1.02
IRB 3/12/02 |
MULTIPLE MYELOMA: Autologous peripheral stem cell transplantation for multiple myeloma: Safety and efficacy of the use of Rituxan for in vivo purging prior to high-dose chemotherapy and peripheral stem cell transplantation in the treatment of multiple myeloma.
* Tulane investigator-initiated. |
SWOG # S0115 71
transplant
IRB 07/15/2004 |
A Phase II trial evaluating modified high-dose Melphalan (100 mg/m2) and autologous peripheral blood stem cell supported transplantation (SCT) for high-risk patients with multiple myeloma and/or light chain amyloidosis. BMT
|
SWOG 20 # S0309 72
transplant
IRB 07/15/2004 |
Myeloma specimen repository protocol, ancillary.
|
MAC 001 73
IRB 07/29/2004 |
A prospective, open-label, safety and efficacy study of combination treatment with Melphalan, Arsenic Trioxide acid in patients with relapsed or refractory myeloma.
|
| COG # A3961 74 |
Treatment for infants and children with intermediate risk neuroblastoma. |
| COG # A3973 75 |
A randomized study of purged vs. unpurged PBSC transplant following dose-intensive induction therapy for high-risk NBL. |
| COG # ANBL00B1 |
Neuroblastoma biology studies. |
COG #
P9641 76
Closed |
Primary surgical therapy for biologically defined low-risk neuroblastoma. |
AMC # #036 1
IRB 07/07/2003 |
A randomized Phase II trial of topical Halofuginone in patients with HIV-related Kaposi's sarcoma.
|
RTOG # 03-30 77
IRB 09/20/2004 |
A pilot Phase II study of pre-operative radiation therapy and thalidomide (IND 48832; NSC 66847)
for low-grade primary soft tissue sarcoma or pre-operative Maid/Thalidomide/radiation therapy for high/intermediate-grade
primary soft tissue sarcoma of the extremity or body wall. Details 78 on RTOG website in PDF format.
|
| COG # AEWS0031 79 |
EWINGS SARCOMA: Trial of chemotherapy intensification through interval compression in Ewing's Sarcoma and related tumors
|
| COG # AOST0121 80 |
OSTEOGENIC SARCOMA: A group-wide Phase II study of Trastuzumab (Herceptin) in metastatic osteosarcoma patients with tumors that over-express HER2.
|
| COG # P9851 |
OSTEOGENIC SARCOMA: Biology studies in osteosarcoma: Companion study to intergroup therapeutic.
|
COG # IRSG
D9602 81
Closed |
RHABDOMYOSARCOMA: Actinomycin D & Vincristine with or without radiation therapy for newly-diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma or undifferentiated sarcoma: An IRS-V protocol.
|
| COG # IRSG D9802 82 |
RHABDOMYOSARCOMA: A Phase II study of Irinotecan (CPT-11) combined with vincristine followed by multimodal, multi-agent therapy for selected children and adolescents with newly-diagnosed stage IV/clinical group IV rhabdomyosarcoma. An IRS-V protocol.
|
COG #
IRSG D9803 83
Temporarily Closed to Accrual |
RHABDOMYOSARCOMA: Randomized study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) vs. VAC alternating with Vincristine, Topotecan, and Cyclophosphamide for patients with intermediate-risk rhabdomyosarcoma
|
| COG # ARST 0121 |
RHABDOMYOSARCOMA: A groupwide protocol for collecting and banking pediatric cancer research specimens. An intergroup rhabdomyosarcoma study group protocol.
|
| COG # ARST 0121 84 |
RHABDOMYOSARCOMA: Group-wide randomized Phase II window study of two different schedules of Irinotecan in combination with Vincristine and pilot assessment of safety and efficacy of Tirapazamine combined with multi-agent chemotherapy for first relapse or progressive disease in rhabdomyosacroma and related tumors.
|
Tulane BMT # 2001-01
IRB 2/8/2001 |
G-CSF primed donor leukocyte infusion (G-DLI) for treatment of relapsed hematologic malignancy after allogeneic stem cell transplant.
|
Tulane BMT # 2001-03
IRB 7/17/2001 |
Phase II trial of CD34 selected peripheral blood progenitor cells with immunoablation in the treatment of severe autoimmune disease
|
Tulane # TC01.1
IRB 10/30/01 |
(DC1s and DC2s) Dendritic cells in hematologic malignancies.
* Tulane investigator-initiated study |
Tulane # TC01.2
IRB 07/17/02 |
Evaluation of the immunologic consequences of circulating nucleated red blood cells
* Tulane investigator-initiated study |
Tulane # TC01.3
IRB 10/01/2003 |
Phase I/II dose escalation trial of intravenous Ontak to enhance tumor immunity in patients with cancer.
* Tulane investigator-initiated study |
RTOG # 03-15 85
IRB 07/20/2004 |
A randomized, double-blind, placebo-controlled Phase III study to determine the efficacy of Sandostatin LAR (Ochtreotide Acetate) in preventing or reducing the Severity of chemoradiation-induced diarrhea in patients with anal or rectal cancer.
Details 14 on RTOG website in PDF format. |
|
| 1 | http://cancer.gov/clinicaltrials/AMC-036 |
| 2 | http://cancer.gov/clinicaltrials/COG-A9952 |
| 3 | http://cancer.gov/clinicaltrials/COG-P9934 |
| 4 | http://cancer.gov/clinicaltrials/RTOG-0420 |
| 5 | http://cancer.gov/clinicaltrials/NSABP-B-35 |
| 6 | http://cancer.gov/clinicaltrials/NSABP-B-36 |
| 7 | http://cancer.gov/clinicaltrials/NSABP-B-38 |
| 8 | http://cancer.gov/clinicaltrials/NSABP-P-2 |
| 9 | http://f5.grp.yahoofs.com/v1/star.html |
| 10 | http://www.nsabp.pitt.edu/STAR/index.html |
| 11 | http://cancer.gov/clinicaltrials/SWOG-S0221 |
| 12 | http://cancer.gov/clinicaltrials/SWOG-S0338 |
| 13 | http://cancer.gov/clinicaltrials/RTOG-0315 |
| 14 | http://www.rtog.org/members/protocols/0315/0315.pdf |
| 15 | http://cancer.gov/clinicaltrials/NSABP-C-08 |
| 16 | http://cancer.gov/clinicaltrials/NSABP-R-04 |
| 17 | http://cancer.gov/clinicaltrials/SWOG-S0415 |
| 18 | http://cancer.gov/clinicaltrials/TBC-PAN-003 |
| 19 | http://www.cancer.gov/clinicaltrials/SWOG-4B951 |
| 20 | http://www.swog.org |
| 21 | http://www.swog.org/visitors/ViewProtocolDetails.asp?ProtocolID=7 |
| 22 | http://www.cancer.gov/clinicaltrials/SWOG-S0000 |
| 23 | http://www.swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=1867 |
| 24 | http://www.cancer.gov/clinicaltrials/SWOG-9346 |
| 25 | http://www.cancer.gov/clinicaltrials/SWOG-S9917 |
| 26 | http://www.cancer.gov/clinicaltrials/SWOG-S9921 |
| 27 | http://www.cancer.gov/clinicaltrials/CAN-NCIC-PR3 |
| 28 | http://www.cancer.gov/clinicaltrials/CAN-NCIC-PR7 |
| 29 | http://www.cancer.gov/clinicaltrials/COG-Q9401 |
| 30 | http://www.cancer.gov/clinicaltrials/COG-Q9402 |
| 31 | http://www.cancer.gov/clinicaltrials/GOG-0179 |
| 32 | http://www.cancer.gov/clinicaltrials/GOG-0191 |
| 33 | http://www.cancer.gov/clinicaltrials/GOG-0137A |
| 34 | http://www.cancer.gov/clinicaltrials/GOG-0184 |
| 35 | http://www.som.tulane.edu/medhemonc/Trials/Index.htm |
| 36 | http://www.cancer.gov/clinicaltrials/GOG-175 |
| 37 | http://www.cancer.gov/clinicaltrials/GOG-0182 |
| 38 | http://www.cancer.gov/clinicaltrials/GOG-0199 |
| 39 | http://www.cancer.gov/clinicaltrials/GOG-161 |
| 40 | http://www.cancer.gov/clinicaltrials/GOG-174 |
| 41 | http://www.cancer.gov/clinicaltrials/GOG-176 |
| 42 | http://www.cancer.gov/clinicaltrials/RTOG-0225 |
| 43 | http://www.cancer.gov/clinicaltrials/RTOG-0234 |
| 44 | http://www.rtog.org/members/protocols/0234/0234.pdf |
| 45 | http://www.swog.org/visitors/ViewProtocolDetails.asp?ProtocolID=4 |
| 46 | http://f5.grp.yahoofs.com/v1/4IklQ2p47gwh5H4oXCWTWf7k8urk1hn4aWWrBokqcwNdJorDwR
PJRqttZvr7LvT8doC0S2tOVXcfH_OkAHRAZTuVk0eTaNZLIm_K/www.swog.org/visitors/ViewPr
otocolDetails.asp?ProtocolID=57 |
| 47 | http://www.cancer.gov/clinicaltrials/SWOG-S0301 |
| 48 | http://www.cancer.gov/clinicaltrials/SWOG-S0432 |
| 49 | http://www.childrensoncologygroup.org |
| 50 | http://www.cancer.gov/clinicaltrials/COG-P9407 |
| 51 | http://www.cancer.gov/clinicaltrials/COG-P9904 |
| 52 | http://www.cancer.gov/clinicaltrials/COG-P9905 |
| 53 | http://www.cancer.gov/clinicaltrials/COG-AALL0031 |
| 54 | http://www.cancer.gov/clinicaltrials/COG-ADVL0022 |
| 55 | http://www.cancer.gov/clinicaltrials/COG-ADVL0023 |
| 56 | http://www.cancer.gov/clinicaltrials/COG-ADVL0122 |
| 57 | http://cancer.gov/clinicaltrials/NCCTG-N9945 |
| 58 | http://cancer.gov/clinicaltrials/COG-P9645 |
| 59 | http://www.swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=1816 |
| 60 | http://cancer.gov/clinicaltrials/SWOG-S0310 |
| 61 | http://cancer.gov/clinicaltrials/SWOG-S0124 |
| 62 | http://www.cancer.gov/clinicaltrials/ECOG-5597 |
| 63 | http://www.cancer.gov/clinicaltrials/SWOG-S0342 |
| 64 | http://www.cancer.gov/clinicaltrials/RTOG-0236 |
| 65 | http://www.rtog.org/members/protocols/0236/0236.pdf |
| 66 | http://www.cancer.gov/clinicaltrials/ECOG-2496 |
| 67 | http://www.cancer.gov/clinicaltrials/COG-AHOD0031 |
| 68 | http://www.cancer.gov/clinicaltrials/COG-AHOD00P1 |
| 69 | http://cancer.gov/clinicaltrials/SWOG-S9704 |
| 70 | http://cancer.gov/clinicaltrials/COG-A5971 |
| 71 | http://cancer.gov/clinicaltrials/SWOG-S0115 |
| 72 | http://www.swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=1928 |
| 73 | http://cancer.gov/clinicaltrials/ONCOTHER-MAC001 |
| 74 | http://cancer.gov/clinicaltrials/COG-A3961 |
| 75 | http://cancer.gov/clinicaltrials/COG-A3973 |
| 76 | http://cancer.gov/clinicaltrials/COG-P9641 |
| 77 | http://cancer.gov/clinicaltrials/RTOG-0330 |
| 78 | http://www.rtog.org/members/protocols/0330/0330.pdf |
| 79 | http://cancer.gov/clinicaltrials/COG-AEWS0031 |
| 80 | http://cancer.gov/clinicaltrials/COG-AOST0121 |
| 81 | http://cancer.gov/clinicaltrials/COG-D9602 |
| 82 | http://cancer.gov/clinicaltrials/COG-D9802 |
| 83 | http://cancer.gov/clinicaltrials/COG-D9803 |
| 84 | http://cancer.gov/clinicaltrials/COG-ARST0121 |
| 85 | http://www.cancer.gov/clinicaltrials/RTOG-0315 |
